| P50 | author | Christian Barro | Q60690467 |
| | Tanuja Chitnis | Q30353265 |
| | Rohit Bakshi | Q56515975 |
| P2093 | author name string | Harald Kropshofer | |
| | Howard L Weiner | |
| | David Leppert | |
| | Ludwig Kappos | |
| | Jens Kuhle | |
| | Anu Paul | |
| | Bonnie I Glanz | |
| | Brian C Healy | |
| | Davorka Tomic | |
| | Pia Kivisakk | |
| | Zuzanna Michalak | |
| | Camilo Diaz-Cruz | |
| | Mattia Rosso | |
| | Shrishti Saxena | |
| | Cindy Gonzalez | |
| | Neda Sattarnezhad | |
| | Dieter Häring | |
| | Isabelle V Pierre | |
| P2860 | cites work | Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease | Q80090456 |
| | Neurofilament light as a prognostic marker in multiple sclerosis | Q82566866 |
| | Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis | Q86613307 |
| | Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis | Q87269296 |
| | Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria | Q24605493 |
| | Neurofilament in CSF-A biomarker of disease activity and long-term prognosis in multiple sclerosis | Q28276772 |
| | Validity of the Symbol Digit Modalities Test as a cognition performance outcome measure for multiple sclerosis | Q33605353 |
| | Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis | Q34975529 |
| | Increased neurofilament light chain blood levels in neurodegenerative neurological diseases | Q35000781 |
| | Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis | Q35330799 |
| | Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis | Q35537489 |
| | Exploration of machine learning techniques in predicting multiple sclerosis disease course | Q36335905 |
| | A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study | Q36617521 |
| | The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis | Q37325966 |
| | Central fatigue in multiple sclerosis: a review of the literature | Q37404024 |
| | The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? | Q37427659 |
| | Serum neurofilament is associated with progression of brain atrophy and disability in early MS. | Q38381437 |
| | Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis | Q38682945 |
| | Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa | Q38882174 |
| | Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome | Q39035274 |
| | Psychometric properties of the modified fatigue impact scale | Q39266465 |
| | Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. | Q40864697 |
| | A role for neurofilaments in the pathogenesis of amyotrophic lateral sclerosis | Q41037886 |
| | Neurofilaments consist of distinct populations that can be distinguished by C-terminal phosphorylation, bundling, and axonal transport rate in growing axonal neurites. | Q43551089 |
| | Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. | Q44028578 |
| | The relationship between diffuse axonal damage and fatigue in multiple sclerosis | Q44766912 |
| | Serum neurofilament light chain is a biomarker of human spinal cord injury severity and outcome | Q45284798 |
| | Neurofilament light chain predicts disease activity in relapsing-remitting MS. | Q47138197 |
| | Monitoring disease activity in multiple sclerosis using serum neurofilament light protein | Q47144073 |
| | Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration | Q47165587 |
| | Dual-Sensitivity Multiple Sclerosis Lesion and CSF Segmentation for Multichannel 3T Brain MRI. | Q47918457 |
| | Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease | Q48243501 |
| | Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases | Q48682038 |
| | Neurofilament light chain in cerebrospinal fluid and prediction of disease activity in clinically isolated syndrome and relapsing-remitting multiple sclerosis. | Q51110507 |
| | Fatigue and declines in cognitive functioning in multiple sclerosis. | Q51972539 |
| | Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod. | Q53212006 |
| | Cerebrospinal fluid biomarkers of inflammation and degeneration as measures of fingolimod efficacy in multiple sclerosis. | Q53624114 |
| | The prognostic value of CSF neurofilaments in multiple sclerosis at 15-year follow-up. | Q53636788 |
| P433 | issue | 12 | |
| P304 | page(s) | 1478-1491 | |
| P577 | publication date | 2018-10-16 | |
| P1433 | published in | Annals of clinical and translational neurology | Q27725312 |
| P1476 | title | Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis | |
| P478 | volume | 5 | |